@BCRT@ProfAllieG@sheffielduni Hello. Could you please provide more insight on this tweet? It was a question, but it's it a consideration one should have?
Approximately 85% of chondrosarcoma cases are of the conventional subtype, while the remaining 15% include dedifferentiated, mesenchymal, and clear-cell subtypes https://t.co/DqBR9VH5Tg
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease
✏️ Vikram Deshpande 2 3 (@Vik_deshpandeMD)
🗓️ 2021 Apr 12
🌐 https://t.co/wvEzf0lids
#MGHPathPublication
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study https://t.co/s8DJHz9SxW
Dedifferentiated chondrosarcoma is a chondrosarcoma subtype associated w/ ⬆️ rates of recurrence
Chemotherapy has been proposed as a treatment option, but management remains controversial
Is chemo associated w/ improved OS in those w/ DDCS? @fredhutch
https://t.co/BZCPvPRVxp
New from Cancer Control: Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2
https://t.co/Jwg6ddPK6H
#SAGEResearch#openaccess#CancerResearch
Yes. This is indeed a great study..we got good response in #chondrosarcoma (dediff) with pembrolizumab..after going though this study only we started that..
The role of #CT for #patients with dedifferentiated #chondrosarcoma is still under discussion‼️
This article showed that adding intensive CT to #surgery for treatment of DDCS is feasible and shows favourable #survival data compared with previous reports👏
https://t.co/veIiR9PghL